Core Viewpoint - The article discusses the upcoming first Global Aesthetic Technology Conference, highlighting its significance in the medical aesthetics industry and the various activities planned for the event [1][2]. Event Details - The event is scheduled for June 12, 2025, at the Zhongguancun Exhibition Center in Beijing, with an expected attendance of 500 participants [1]. - The conference is organized by Siyu MedTech and Tanmei Medical, with support from various industry alliances and incubators [1]. Agenda Highlights - The agenda includes a series of speeches, award ceremonies, and the launch of the "Third Aesthetic Surgery Innovation Transformation Competition" [2]. - Key presentations will cover topics such as stem cell industry trends, skin management, and the role of medical animal experiments in product development [2]. - A roundtable discussion on the innovation path of aesthetic technology will feature prominent industry experts [2]. Registration and Participation - Attendees can register for the event using a discount code, allowing free entry for those who apply [4][5]. - There are additional networking opportunities planned for industry professionals in the afternoon [1][5].

Group 1 - The Hang Seng Healthcare Index (HSHCI) has seen a strong increase of 1.80%, with notable gains from companies such as Lepu Biopharma-B (up 16.56%) and Zai Lab (up 10.27%) [1] - The Hang Seng Medical ETF (513060) has risen by 2.11%, marking its third consecutive increase, with a trading volume of 4.69 billion yuan [1][2] - The second Boao Lecheng Stem Cell Conference has opened, marking a new phase of standardized and high-quality development in China's stem cell industry [2] Group 2 - Financial analysts predict that the approval and implementation of more projects in the stem cell sector will lead to advanced treatment methods benefiting the public [2] - The domestic medical innovation industry is expected to experience multiple growth opportunities, particularly for companies with true innovation capabilities in new drug development [2] - The Hang Seng Medical ETF has seen a significant growth in scale, increasing by 34.09 billion yuan over the past year, ranking in the top third among comparable funds [2] Group 3 - Since its inception, the Hang Seng Medical ETF has achieved a maximum monthly return of 28.34% and an average monthly return of 7.00% [3] - The ETF has outperformed its benchmark with an annualized excess return of 2.02% over the past year [3] - The ETF's management fee is 0.50%, and the custody fee is 0.15% [3] Group 4 - The tracking error of the Hang Seng Medical ETF is 0.033%, the highest tracking precision among comparable funds [4] - The latest price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is 24.97, indicating it is at a historical low compared to the past year [4] - The top ten weighted stocks in the Hang Seng Medical Healthcare Index account for 55.64% of the index, with companies like WuXi Biologics and BeiGene among the leaders [4][6]